Stifel reiterates argenx stock Buy rating after trial stopped
Stifel maintained a Buy rating and $1,282 price target for argenx (ARGX) despite a Phase 3 trial halt for futility. The stock trades at $812.86, with a Fair Value estimate of $1,087.81. Analysts remain optimistic about other label expansions and upcoming data. Argenx reported 70% revenue growth and strong financial health. Other analysts have mixed ratings and price targets.
How this was made
The 30-second read
Why it matters
The negative trial result is expected to depress the stock, though other pipeline programs may mitigate the decline.
Market read
Primary biotech news with direct impact on ARGX's valuation and potential sector ripple.
What to watch
Cash position remains strong and recent positive Phase 2 data in other indications could support a rebound.
Background
argenx (NASDAQ:ARGX) halted a Phase 3 study for efgartigimod in Sjogren’s disease after a futility assessment, while analysts adjusted price targets.
Ticker impact
Stifel reiterated a Buy rating after argenx stopped its Phase 3 trial of efgartigimod in Sjogren’s disease for futility.
likely pressure as the market prices in the negative trial outcome
Phase 3 failure is material news for a biotech; investors typically react with downside pressure.
Market effects
May weigh on other autoimmune‑disease biotech peers as trial risk perception rises.
Limited to US biotech sector; no broader regional effect.
Modest global relevance, confined to specialty pharma investors.
Counterpoint
Some analysts still see upside from other pipeline assets and label expansion in myasthenia gravis.
Key entities
- analystStifel
Equity research firm reiterating a Buy rating on ARGX.
- analystUBS
Upgraded ARGX to Buy with higher price target.
